This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Trimetrexate glucuronate
Description: The active ingredient of Neutrexin, trimetrexate glucuronate, is a non-classical folate antagonist. It inhibits the enzyme dihydrofolate reductase (DHFR), an important ezyme in purine biosynthesis, resulting in the disruption of DNA, RNA, and protein synthesis which leads to cell death.
Deal Structure: NeuTrexin was originally developed by MedImmune; in June 2007, AstraZeneca closed its acquisition of MedImmune.
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. The acquisition was completed in November 2009.
Partners: Merck & Co., Inc.
Pink Sheet In Brief: U.S. Bioscience
Pink Sheet U.S. Bioscience's NeuTrexin
Additional information available to subscribers only: